Open questions between immune checkpoint inhibitors and tuberculosis incidence
Authors:
Open Access
- 1 August 2024
- journal article
- letter
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (8) , 5484-5486
Abstract
Open questions between immune checkpoint inhibitors and tuberculosis incidenceKeywords
This publication has 10 references indexed in Scilit:
- A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?Journal of Thoracic Disease, 2024
- Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based TherapyThe Oncologist, 2024
- Risk Factors for Pulmonary Tuberculosis in Patients with Lung Cancer: A Retrospective Cohort StudyJournal of Cancer, 2023
- PD-1 Inhibitor for Disseminated Mycobacterium avium Infection in a Person With HIVOpen Forum Infectious Diseases, 2022
- The Prevalence of Mycobacterium tuberculosis Infection Among Cancer Patients Receiving Chemotherapy in a Tertiary Care CenterCureus, 2022
- Infections due to dysregulated immunity: an emerging complication of cancer immunotherapyThorax, 2021
- Organizing pneumonia-presenting acute respiratory distress syndrome because of paradoxical tuberculosis-immune reconstitution disease?AIDS, 2021
- Implications of Tuberculosis Reactivation after Immune Checkpoint InhibitionAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literatureBMC Infectious Diseases, 2012
- Programmed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosisProceedings of the National Academy of Sciences, 2010